or Try an Advanced Search...

    Technical Analysis for NKGN - NKGen Biotech, Inc.

    Grade Last Price % Change Price Change
    F 0.27 -3.08% -0.01
    NKGN closed down 3.08 percent on Friday, November 1, 2024, on 49 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical NKGN trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    Hammer Candlestick Bullish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    1,2,3 Pullback Bullish Bullish Swing Setup -3.08%
    NR7 Range Contraction -3.08%
    Older End-of-Day Signals for NKGN ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 21 hours ago
    Down 3% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 2 % about 21 hours ago
    Down 1% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NKGN Chart by TradingView
    Basic chart:

    Profile

    NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immune System Stem Cell Cell Therapy Cell Biology Natural Killer Cell Lymphocytes

    Is NKGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 29 NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    Oct 15 NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
    Oct 8 NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    Sep 17 Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Sep 12 NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
    Sep 3 NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 22 NKGen Biotech receives non-compliance notification from Nasdaq
    Aug 22 NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
    Jul 30 NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
    Jul 22 Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
    See more NKGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.06
    52 Week Low 0.2026
    Average Volume 1,305,105
    200-Day Moving Average 1.19
    50-Day Moving Average 0.50
    20-Day Moving Average 0.35
    10-Day Moving Average 0.35
    Average True Range 0.09
    RSI (14) 40.12
    ADX 40.8
    +DI 32.93
    -DI 20.78
    Chandelier Exit (Long, 3 ATRs) 0.61
    Chandelier Exit (Short, 3 ATRs) 0.46
    Upper Bollinger Bands 0.55
    Lower Bollinger Band 0.14
    Percent B (%b) 0.3
    BandWidth 116.66
    MACD Line -0.05
    MACD Signal Line -0.05
    MACD Histogram -0.0005
    Fundamentals Value
    Market Cap 5.85 Million
    Num Shares 21.9 Million
    EPS -2.57
    Price-to-Earnings (P/E) Ratio -0.10
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.30
    Resistance 3 (R3) 0.30 0.28 0.30
    Resistance 2 (R2) 0.28 0.28 0.29 0.29
    Resistance 1 (R1) 0.28 0.27 0.28 0.28 0.29
    Pivot Point 0.26 0.26 0.26 0.26 0.26
    Support 1 (S1) 0.25 0.25 0.26 0.26 0.24
    Support 2 (S2) 0.24 0.25 0.24 0.24
    Support 3 (S3) 0.23 0.24 0.24
    Support 4 (S4) 0.23